Bio-Techne Corp.'s Q3 earnings call reveals key financial performance metrics, strategic initiatives, and a positive outlook for future growth in the biopharma sector.
Bio-Techne Corp. recently held its earnings call for the third quarter of fiscal 2026, revealing significant insights into its financial performance, strategic initiatives, and future outlook. The company reported a mixed performance across its segments, with notable growth in its spatial biology portfolio and strong profitability metrics. As the biotechnology landscape continues to evolve, Bio-Techne remains well-positioned to capitalize on emerging opportunities, particularly in the biopharma sector.
Financial Performance
In the third quarter, Bio-Techne reported total revenue of $311.4 million, reflecting a 2% decline on both an organic and reported basis. However, when adjusting for certain factors, organic growth was a modest 2%. Key highlights from the earnings call include:
- Adjusted EPS: The adjusted earnings per share was $0.53, a decrease of $0.03 from the previous year.
- GAAP EPS: The generally accepted accounting principles earnings per share rose to $0.32, compared to $0.14 in the same period last year.
- Revenue Breakdown: The decline in revenue was attributed to several factors:
- A 3% headwind from order timing related to major cell therapy customers.
- A 1% impact from a large OEM commercial supply order that was received in Q2 instead of Q3.
- Foreign currency exchange positively impacted revenue by 2%.
From a geographic perspective, Bio-Techne's performance varied:
- North America: Revenue declined low single digits.
- Europe: Achieved mid-single digit growth.
- China: Continued to show positive organic growth for the fourth consecutive quarter.
The company reported an adjusted operating margin of 34.2%, an increase of 310 basis points sequentially, which underscores its focus on maintaining profitability amidst a challenging environment.
Strategic Initiatives
Bio-Techne continues to innovate and streamline its product offerings. In April, the company announced a strategic brand alignment that consolidated its portfolio from ten brands down to three, enhancing customer engagement and simplifying product navigation:
- R&D Systems: Integrates a comprehensive portfolio of research and GMP reagents.
- Bio-Techne Spatial Biology: Includes RNA scope and the COMET Multiomics Spatial platform.
- Bio-Techne Diagnostics: Encompasses clinical controls and precision diagnostics solutions.
The alignment is designed to better support customers as they progress from discovery to clinical and diagnostic applications, particularly in the growing fields of artificial intelligence (AI) and drug discovery. AI is increasingly influencing both operational efficiency and customer strategies, with Bio-Techne leveraging its proprietary data to develop novel proteins with enhanced properties.
Key developments in the company's product segments include:
- Spatial Biology: The COMET platform saw over 65% growth, with record backlogs indicating strong future demand.
- Proteomic Analysis: The ELLA platform is gaining traction in neurodegeneration research, with a three-year CAGR of 50% across its neurology assay portfolio.
- GMP Proteins: Excluding significant customer impacts, revenue grew nearly 50% year-on-year.
Future Outlook
Looking ahead, Bio-Techne's management provided guidance that reflects cautious optimism. The company expects organic growth in the fourth quarter to be approximately flat, considering the impacts of cell therapy headwinds. However, they anticipate low single-digit growth across the portfolio, excluding these factors.
Management expressed confidence in the stability of the biopharma sector, highlighting:
- Sustained engagement from large pharmaceutical customers.
- Positive trends in the US academic market.
- Continued momentum in China and the broader APEC region.
As the company prepares for fiscal 2027, management believes that the improving funding visibility for biotechnology will translate into customer spending, particularly in emerging biotech. They noted:
“While we may not see a meaningful uptick in growth until the first half of fiscal 2027, the indicators are encouraging.”
Investments in growth areas such as cell therapy, spatial biology, and precision diagnostics position Bio-Techne to capture attractive long-term growth opportunities.
Concluding Assessment
In conclusion, Bio-Techne Corp. demonstrated resilience in its Q3 earnings call, reflecting a commitment to strategic growth amidst market challenges. The company's financial metrics indicate a strong focus on profitability, while its strategic initiatives align well with current trends in biotechnology and drug discovery. Looking ahead, the potential for growth in fiscal 2027 is promising, particularly as funding conditions improve in the biotech sector. As Bio-Techne continues to leverage its innovative product offerings, it remains well-positioned to navigate the evolving landscape of biopharma and diagnostics.
